Richard Kellermayer

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 18

Top Topics

Ulcerative Colitis

Top Venues

Alimentary pharmacology & therapeutics

Inflammatory bowel diseases

Hepatology (Baltimore, Md.)

This page only lists publications with an associated author ORCID identifier.

Publications

Ashleigh Watson, Lina B Karam, Richard Kellermayer
Failure Rate of Anti-Tumor Necrosis Factor α Biologics in Very Early Onset Inflammatory Bowel Disease. Inflammatory bowel diseases 30 (3) (2024)
Richard Kellermayer, Marco Carbone, Thomas D Horvath, Reka G Szigeti, Cynthia W Buness, Gideon M Hirschfield, Peter J Lewindon
Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune-mediated liver injury. Hepatology (Baltimore, Md.) (2024)
Ashleigh Watson, Lina B Karam, Richard Kellermayer
Failure Rate of Anti-Tumor Necrosis Factor α Biologics in Very Early Onset Inflammatory Bowel Disease. Inflammatory bowel diseases 30 (3) (2024)
Ashleigh Watson, R Alan Harris, Amy C Engevik, Numan Oezguen, Maribeth R Nicholson, Sarah Dooley, Rachel Stubler, Lisa Forbes Satter, Lina B Karam, Richard Kellermayer
MYO5B and the Polygenic Landscape of Very Early-Onset Inflammatory Bowel Disease in an Ethnically Diverse Population. Inflammatory bowel diseases (2024)
Ashleigh Watson, Lina B Karam, Richard Kellermayer
Failure Rate of Anti-Tumor Necrosis Factor α Biologics in Very Early Onset Inflammatory Bowel Disease. Inflammatory bowel diseases (2024)
Reka Szigeti, Mahesh Krishna, Richard Kellermayer
Letter: fulminant-onset complicated inflammatory bowel disease (IBD)-a unique subtype? Alimentary pharmacology & therapeutics 57 (10) (2023)
Reka Szigeti, Mahesh Krishna, Richard Kellermayer
Letter: fulminant-onset complicated inflammatory bowel disease (IBD)-a unique subtype? Alimentary pharmacology & therapeutics 57 (10) (2023)
Reka Szigeti, Mahesh Krishna, Richard Kellermayer
Letter: fulminant-onset complicated inflammatory bowel disease (IBD)-a unique subtype? Alimentary pharmacology & therapeutics 57 (10) (2023)
Reka Szigeti, Mahesh Krishna, Richard Kellermayer
Letter: fulminant-onset complicated inflammatory bowel disease (IBD)-a unique subtype? Alimentary pharmacology & therapeutics 57 (10) (2023)
Rajesh R Shah, Kristi Hoffman, Lee Denson, Subramaniam Kugathasan, Richard Kellermayer
Mucosal microbiome is predictive of pediatric Crohn's disease across geographic regions in North America. F1000Research 11 (2022)
Rajesh R Shah, Kristi Hoffman, Lee Denson, Subramaniam Kugathasan, Richard Kellermayer
Mucosal microbiome is predictive of pediatric Crohn's disease across geographic regions in North America. F1000Research 11 (2022)
Rajesh R Shah, Kristi Hoffman, Lee Denson, Subramaniam Kugathasan, Richard Kellermayer
Mucosal microbiome is predictive of pediatric Crohn's disease across geographic regions in North America. F1000Research 11 (2022)
Rajesh R Shah, Kristi Hoffman, Lee Denson, Subramaniam Kugathasan, Richard Kellermayer
Mucosal microbiome is predictive of pediatric Crohn's disease across geographic regions in North America. F1000Research 11 (2022)
Rajesh R Shah, Kristi Hoffman, Lee Denson, Subramaniam Kugathasan, Richard Kellermayer
Mucosal microbiome is predictive of pediatric Crohn's disease across geographic regions in North America. F1000Research 11 (2022)
Rajesh R Shah, Kristi Hoffman, Lee Denson, Subramaniam Kugathasan, Richard Kellermayer
Mucosal microbiome is predictive of pediatric Crohn's disease across geographic regions in North America. F1000Research 11 (2022)
Rajesh R Shah, Kristi Hoffman, Lee Denson, Subramaniam Kugathasan, Richard Kellermayer
Mucosal microbiome is predictive of pediatric Crohn's disease across geographic regions in North America. F1000Research 11 (2022)
Rajesh R Shah, Kristi Hoffman, Lee Denson, Subramaniam Kugathasan, Richard Kellermayer
Mucosal microbiome is predictive of pediatric Crohn's disease across geographic regions in North America. F1000Research 11 (2022)
Reka Szigeti, Domos Kellermayer, Giedrius Trakimas, Richard Kellermayer
BCG epidemiology supports its protection against COVID-19? A word of caution. PloS one 15 (10) (2020)